These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

409 related articles for article (PubMed ID: 35039676)

  • 1. Immune targets for therapeutic development in depression: towards precision medicine.
    Drevets WC; Wittenberg GM; Bullmore ET; Manji HK
    Nat Rev Drug Discov; 2022 Mar; 21(3):224-244. PubMed ID: 35039676
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A clinical approach to treatment resistance in depressed patients: What to do when the usual treatments don't work well enough?
    Dodd S; Bauer M; Carvalho AF; Eyre H; Fava M; Kasper S; Kennedy SH; Khoo JP; Lopez Jaramillo C; Malhi GS; McIntyre RS; Mitchell PB; Castro AMP; Ratheesh A; Severus E; Suppes T; Trivedi MH; Thase ME; Yatham LN; Young AH; Berk M
    World J Biol Psychiatry; 2021 Sep; 22(7):483-494. PubMed ID: 33289425
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Depressive symptoms during anorexia nervosa: State of the art and consequences for an appropriate use of antidepressants].
    Leblé N; Radon L; Rabot M; Godart N
    Encephale; 2017 Feb; 43(1):62-68. PubMed ID: 27452149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuroimmunology of depression.
    Sarno E; Moeser AJ; Robison AJ
    Adv Pharmacol; 2021; 91():259-292. PubMed ID: 34099111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunotherapy for depression: Recent insights and future targets.
    Bai Y; Cai Y; Chang D; Li D; Huo X; Zhu T
    Pharmacol Ther; 2024 May; 257():108624. PubMed ID: 38442780
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Prediction and Personalized Medicine of Antidepressant Treatment in Japanese MDD Patient].
    Kato M
    Seishin Shinkeigaku Zasshi; 2016; 118(3):139-146. PubMed ID: 30620509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nitric oxide: Antidepressant mechanisms and inflammation.
    Ghasemi M
    Adv Pharmacol; 2019; 86():121-152. PubMed ID: 31378250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The establishment of the objective diagnostic markers and personalized medical intervention in patients with major depressive disorder: rationale and protocol.
    Lv X; Si T; Wang G; Wang H; Liu Q; Hu C; Wang J; Su Y; Huang Y; Jiang H; Yu X
    BMC Psychiatry; 2016 Jul; 16():240. PubMed ID: 27422150
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo.
    Fourrier C; Sampson E; Mills NT; Baune BT
    Trials; 2018 Aug; 19(1):447. PubMed ID: 30126458
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Heart rate variability as a biomarker of anxious depression response to antidepressant medication.
    Kircanski K; Williams LM; Gotlib IH
    Depress Anxiety; 2019 Jan; 36(1):63-71. PubMed ID: 30311742
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nitrous Oxide: an emerging novel treatment for treatment-resistant depression.
    Quach DF; de Leon VC; Conway CR
    J Neurol Sci; 2022 Mar; 434():120092. PubMed ID: 34953347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting cytokines in reduction of depressive symptoms: A comprehensive review.
    Shariq AS; Brietzke E; Rosenblat JD; Barendra V; Pan Z; McIntyre RS
    Prog Neuropsychopharmacol Biol Psychiatry; 2018 Apr; 83():86-91. PubMed ID: 29309829
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging role of microRNAs in major depressive disorder and its implication on diagnosis and therapeutic response.
    Zhou L; Zhu Y; Chen W; Tang Y
    J Affect Disord; 2021 May; 286():80-86. PubMed ID: 33714174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Keeping up with the clinical advances: depression.
    Ragguett RM; Tamura JK; McIntyre RS
    CNS Spectr; 2019 Aug; 24(S1):25-37. PubMed ID: 31248466
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cognitive remission: a novel objective for the treatment of major depression?
    Bortolato B; Miskowiak KW; Köhler CA; Maes M; Fernandes BS; Berk M; Carvalho AF
    BMC Med; 2016 Jan; 14():9. PubMed ID: 26801406
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Personalized Antidepressant Selection and Pathway to Novel Treatments: Clinical Utility of Targeting Inflammation.
    Jha MK; Trivedi MH
    Int J Mol Sci; 2018 Jan; 19(1):. PubMed ID: 29329256
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Agomelatine versus other antidepressive agents for major depression.
    Guaiana G; Gupta S; Chiodo D; Davies SJ; Haederle K; Koesters M
    Cochrane Database Syst Rev; 2013 Dec; (12):CD008851. PubMed ID: 24343836
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promising new pharmacological targets for depression: The search for efficacy.
    Tsugiyama LE; Moraes RCM; Moraes YAC; Francis-Oliveira J
    Drug Discov Today; 2023 Dec; 28(12):103804. PubMed ID: 37865307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inflammatory DEpression Advances in Schizophrenia (IDEAS): A precision medicine approach of the national FACE-SZ cohort.
    Fond G; Godin O; Schürhoff F; Berna F; Aouizerate B; Capdevielle D; Chereau I; D'Amato T; Dubertret C; Dubreucq J; Faget C; Leignier S; Lançon C; Mallet J; Marulaz L; Misdrahi D; Passerieux C; Rey R; Schandrin A; Urbach M; Vidailhet P; Leboyer M; ; Boyer L; Llorca PM
    J Affect Disord; 2019 Feb; 245():468-474. PubMed ID: 30428447
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Meta-analysis and meta-regression of omega-3 polyunsaturated fatty acid supplementation for major depressive disorder.
    Mocking RJ; Harmsen I; Assies J; Koeter MW; Ruhé HG; Schene AH
    Transl Psychiatry; 2016 Mar; 6(3):e756. PubMed ID: 26978738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.